medigraphic.com

2002, Número 5

<< Anterior Siguiente >>

Cir Cir 2002; 70 (5)


Manejo del dolor en cáncer

Ricardo Plancarte-Sánchez, José Emilio Mille-Loera, Francisco Javier Mayer-Rivera

Idioma: Español
Referencias bibliográficas: 65
Paginas: 356-368
Archivo PDF: 109.39 Kb.


RESUMEN

En este trabajo se revisan los aspectos fundamentales para tratar el dolor en el paciente con cáncer, después de serias consideraciones fisiopatológicas, epidemiológicas y clínicas, por lo que se plantean diversas alternativas de manejo para controlar el dolor por cáncer. No cabe duda que las organizaciones que se relacionan con la medicina mundial (OMS), han participado activamente dictando recomendaciones y planes de manejo para el control del dolor. Las opciones farmacológicas basadas en la Escalera Analgésica para el control del dolor, las diferentes consideraciones médicas cuando se ha decidido un manejo intervencionista y las diferentes opciones de manejo invasivo para el control del dolor han sido planteadas en este documento. Es de esta manera como se podrá hacer frente a un problema de salud en nuestro país y los síntomas que afectan tan severamente al paciente, su familia y a las instituciones.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Foley KM, Payne RM. In: Terapéutica del dolor. Editorial Interamericana; 1992.Pp.364 and 426.

  2. Organización Mundial de la Salud. Alivio del dolor en cáncer. Geneva, Switzerland: WHO;1987.Pp.21 and 69-72.

  3. Cancer pain release. WHO. Vol. 13. No. 1, 2000.

  4. Cancer pain release. WHO. Vol. 12. No. 2, 1999.

  5. Cancer pain release. WHO. Vol. 4. Nos. 2-3, 1990.

  6. Romero J, Plancarte SR, Amescua C, Luján M. Mexico’s WHO Cancer Pain Relief Program. In: Advances in pain research and therapy. Vol. 167. New York: Raven Press;1990.

  7. IASP Subcommittee of Taxonomy Classification Chronic Pain. Description of chronic pain syndromes and definitions of pain terms. Pain 1986;3(Suppl):S217.

  8. Romero J, Plancarte R, Guerrero G, Amescua C, Liceaga M, Allende S. Prevalencia del dolor por cáncer en una población de pacientes de nuevo ingreso en el Instituto Nacional de Cancerología. J Pain Symptom Manage Summer 1988;3:571.

  9. Lazorthes Y, Boreau F. Douleur et cancer. Douleur actualités. Soci Franc Douleur 1990;10:2,3,8 and 9.

  10. Silva HJ. Dolor por cáncer. Rev Mex Anestesiol 1990;2:51-52.

  11. Guevara U, Roa L. Consideraciones fisiopatológicas sobre el dolor agudo y crónico. Medi Perioper 1997;1:17-25.

  12. Yaksh TL, Chaplan SR. Fisiología y farmacología del dolor neuropático. Clin Anestesiol North Am 1997;Vol. 2.

  13. Clinical practice guideline number 9: management of cancer pain. U.S. Dept. of Health and Human Services. Agency for Health Care Policy and Research (AHCPR#94-0592);1994.

  14. Feurerstein TL. Antidepressiva zur therapie chronischer shemerzen-metaanalyse. Der Schmerz 1997;11:213-226.

  15. Max MB. In: Fields HL, Liebeskind JC, editors. Antidepressants as analgesics. Progress in pain research and management. Vol. 1. Seattle, WA, USA: IASP Press; 1994.Pp.229-246.

  16. Bennett GJ, Xie YK. A peripheral mononeuropathy in rat that produces abnormal pain sensation like those seen in man. Pain 1988;280:1931-1936.

  17. Bennett GJ. An animal model of neuropathic pain: a review. Muscle Nerve 1993;16:1040-1048.

  18. Chapman V, Susuki R, Chamarette HLC, Rygh LJ, Dickenson AH. Effects of systemic carbamazepine and gabapentin on spinal neuronal response in spinal nerve ligated rats. Pain 1998;75:261-272.

  19. Carlton SM, Zhou S. Attenuation of formalin-induced nociceptive behaviors following local peripheral injection of gabapentin. Pain 1998;76:201-207.

  20. Xiao WH, Bennett GJ. Gabapentin has an antinociceptive effect mediated vial spinal site of action in rat model of painful peripheral neuropathy. Analgesia 1996;2:267-273.

  21. Kocsis JD, Honnou O. Gabapentin increases GABA-induced depolarization in rat neonatal optic nerve. Neurosci Lett 1994;169:223-228.

  22. Bennedetti F, Vighetti S, Amnzio M, Casadio C, Oliaro A, Bergamasco B, Maggi G. Dose-response relationship of opioid in nociceptive and neuropathic postoperative pain. Pain 1998;74:205-211.

  23. Wolfgang K. Low dose of lidocaine reduces secondary hyperalgesia by central mode action. Pain 2000;85:217-224.

  24. Swerdiow & Ventafridda. Cancer pain. MTP Press Limited; 1987.Pp.57-61.

  25. Banning A, Sjogren P, Henriksen H. Pain causes in 200 patients referred to a multidisciplinary cancer pain clinic. Pain 1991;45:45-48.

  26. Zakrzewska JM, Thomas DG. Patient’s assessments of outcome after three surgical procedures for management of trigeminal neuralgia. Acta Neurochir 1993;122:225-230.

  27. Tew JM, Keiller JP. The treatment of trigeminal by percutaneous radiofrequency technique. Clin Neur Surg 1977;557-578.

  28. Tasker RR. Neurosurgical and neuroaugmentative intervention. In: Patt RB, Cancer pain. Philadelphia, PA, USA: JB Lippincott;1993.

  29. Woodruf R. Dolor por cáncer. Medigraphic Ed;1997.Pp.7-8.

  30. Dubois RN, Abramson SB, Crofford L, et al. Cyclooxigenase in biology and disease. Faseb J 1998;1063-1073.

  31. Cherng CH, Wong CS, Ho ST. Spinal action of non-steroidal antiinflammatory drugs. Acta Anaesthesiol 1996;34:81-88.

  32. Benzon HT. Epidural steroid injections for low back pain and lumbosacral radiculopathy. Pain 1986;24:227-295.

  33. Bonica JJ. The management of pain. Vols. 1 and 2. 2nd edition. Philadelphia, PA, USA: Lea and Febiger;1990.

  34. Pichard-Leandry E. La codeíne en cancerologie. Instituto Gustave-Roussy y Gazette Médical Paris 1987;25:56 and 57.

  35. Carr D. Opioids. Int Anesthesiol Clin 1988;26:273-287.

  36. Osipova NA, Novikoy GA, Beresnev VA, Loseva NA. Analgesic effect of tramadol in cancer patients with chronic pain: a comparison with prolonged-action morphine sulfate. Curr Ther Res 1991;50:812-821.

  37. McQuay HG. Clinical effects of buprenophene during after operation. Br J Anaesthesiol 1980;52:1013-1019.

  38. Yaksh TL. Multiple opioid receptor system in brain and spinal cord. Part 1. Eur J Anaesthesiol 1984;179-199.

  39. Jaffe J, Martin W. Opioid analgesic and antagonic. In: Gilman A, et al., editors. Goodman’s and Gilman’s. The Pharmacological basis of therapeutic New York: Pergammon Press;1990.

  40. Stein C, Yassouridis. Acción analgésica periférica de la morfina. Edit Rev Soc Esp Dolor 1998;5:3-7.

  41. Stein C. The control of pain in peripheral tissue by opioids. N Engl J Med 1995;332:1685-1690.

  42. Borsook D, LeBel A, McPeek B. Massachusetts General Hospital Pain treatment Marban;1999.Pp.47-75.

  43. Grond S, Radbruch L, Lehmann A. Clinical pharmacokinetics of transdermal opioids. Clin Pharmacokinetics Jan 2000;59-89.

  44. Walsh DT. Cancer pain. In: Walsh DT, editor. Symptom control. Australia: Blackwell Scientific Publications;1988.Pp.329-365.

  45. Plancarte R, Velázquez SR. Palliative regional anesthesia for hospitalized patients. Curr Opin Anesthesiol 1994;7:444-447.

  46. Abrams S. Neurolytic blocks of peripheral nerves. In: Racz GB, editor. Techniques of neurolysis. Boston, MA, USA: Kluwer;1989.p.185.

  47. Patt R. Peripheral neurolysis. In: Patt R, editor. Cancer pain. JB Lippincott;1993.p.359.

  48. Plancarte R, Velázquez R, Patt RB. Cancer pain. Eur J Palliative Care 1993;377-425.

  49. Patt R, Plancarte R. Superior hypogastric plexus block: a new therapeutic approach for pelvic pain. Interventional pain management. W.B. Saunders Company;1996.Pp.384-391.

  50. Plancarte R, Velázquez R, Patt R. Neurolytic blocks of sympathetic axis. In: Patt R, editor. Cancer pain. JB Lippincott Company;1993.p.377.

  51. Patt R, Plancarte R. Superior hypogastric plexus and ganglion impar. In: Hanh MB, McQuillan PM, Sheplock GJ, editors. Regional anesthesia, an atlas. Anatomy and techniques. USA: Mosby;1996.p.163.

  52. Patt R, Black RG.T Cancer Bull 1995;47(1):52-60.

  53. Curley J, Castillo J, Hotz J, Uezono M, Hernández S, Lim JO, Tigner J, Chasin M, Langer R, Berde CH. Prolonged regional nerve blockade. Injectable biodegradable bupivacaine polyester microspheres. Anesthesiology 1996;84(6):1402-1410.

  54. Thomas S. Image-guided pain management. In: Thomas PS, editor. Philadelphia, PA, USA: Lippincott-Raven Publishers;1997.

  55. Rosier RN. Orthopedic management of cancer pain. In: Patt RB, Editor. Cancer pain. Philadelphia, PA, USA: JB Lippincott Company;1993. Pp.461-468.

  56. Boas RA. The sympathetic nervous system and pain relief. In: Swerdlow M, Charlton JE, editors. Relief of intractable pain. Amsterdam: Elsevier;1989.p.259.

  57. Alon P, Winnie. Neurolytic nerves blocks. Current Rev Pain 1994;5:70-77.

  58. Raj PP, Ramamurthy S. Differential nerve block studies. In: Raj PP, editor. Practical management of pain. Chicago: Year Book;1986.p.173.

  59. Myers DP, Lema MJ, de León-Casasola OA, Bacon DR. Interpleural analgesia for the treatment of severe cancer pain in terminally ill patients. J Pain Symptom Manage 1993;8(7):505-510.

  60. Lema MJ, Myers DP, de León-Casasola OA, Penetrante R. Pleural phenol therapy for the treatment of chronic esophageal cancer pain. Reg Anesth 1992;17(3):166-170.

  61. Cousins MJ. Anesthetic approaches in cancer pain. In: Foley KM, Bonica JJ, Ventafridda V, editors. Advances in pain research and therapy. New York: Raven Press 1988;16:249-273.

  62. Plancarte R, Amezcua C, Patt R. Superior hypogastric plexus block for pelvic cancer pain. Anesthesiology 1990;73:236.

  63. De León-Casasola OA. Superior hypogastric plexus block techniques in regional anesthesia & pain management. 1997;1(1):27-31.

  64. De León-Casasola OA. Postoperative pain management in patients with cancer. Is there more beyond pain control? In: Lema M, guest Editor, Kirby R, Brown D, editors. Problems in anesthesia. Cancer pain management. Philadelphia, PA, USA: JB Lippincott;1993.Pp.474-485.

  65. Plancarte R, Amescua C, Aldrete JA. Hypogastric plexus block. Retroperitoneal approach. Anesthesiology 1989;71:739.




2020     |     www.medigraphic.com